One of the biggest meetings of the world’s cancer specialists took place this weekend. Usually located in Chicago, researchers and clinicians around the world met virtually this year to present the latest in cancer research at the American Society of Clinical Oncology (ASCO) annual meeting. Here’s a flavour of the some of the top research presented.
Widely-used anti-inflammatory drugs make tumours in mice more responsive to treatments that harness the power of the body’s own immune system to tackle cancer, according to research funded by Cancer Research UK and published in the journal Cancer Discovery.
Cancer Research UK estimates that 3 million fewer people were screened for cancer between March and September last year, meaning around 9,200 fewer patients started cancer treatment as a result in England alone – a 42% drop.
We explore how our partner, Credit Suisse, adapted to significant changes in the fundraising environment to exceed its original targets for the partnership.
Cancer Research UK’s spinout, Achilles Therapeutics plc (‘Achilles’), has raised $175.5 million through the closing of its initial public offering (IPO).
Payam Gammage believes understanding the mutations in mtDNA could reveal indicators of cancer prognosis and a new focus for therapeutics.
Cancer Research UK scientists in collaboration with Roche have developed a new antibody that can target CD25 and harness the immune system against cancer.
Joining forces with Children with Cancer UK, we’re proud to be co-funding the Cancer Research UK–Children with Cancer UK Innovation Awards.
A potentially life-extending treatment for some people with non small cell lung cancer (NSCLC) will now be available on the NHS in England.